Assessment of myocardial scar; Comparison between 18F-FDG PET, CMR and 99Tc-Sestamibi

Clinical Medicine: Cardiology

Volumn 2009, Issue 3, 2009, Pages 69-76

  Crean, Andrew ^b   Khan, Sadia N ^a   Davies, L Ceri ^a   Coulden, Richard ^b   Dutka, David P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

CMR; Heart failure; Hibernation; MIBI; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DESCRIPTIVE RESEARCH; DISEASE CLASSIFICATION; FEMALE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE INJURY; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; TERTIARY HEALTH CARE;

EID: 70349623942     PISSN: None     EISSN: 11781165     Source Type: Journal    
DOI: 10.4137/cmc.s730     Document Type: Article

References (33)

1. Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. Am Heart J. 1991;121:1852.3.
2. Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 2001;22(3):228-36.
3. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999; 20(6):421-8.
4. Marwick T. The viable myocardium: epidemiology, detection, and clinical implications. Lancet. 1998;351:815-19.
5. Trachiotis GD, Weintraub WS, Johnston T, et al. Coronary artery bypass grafting in patients with advanced left ventricular dysfunction. Ann Thorac Surg. 1998;66:1632-9.
6. Mickleborough LL, Carson S, Tamariz M, et al. Results of revascularization in patients with severe left ventricular dysfunction. J Thorac Cardiovasc Surg. 2000;119:550-7.
7. Elefteriades JA, Kron IL. CABG in advanced left ventricular dysfunction. Cardiol Clin. 1995;13:35-42.
8. Antunes PE, Oliveira JF, Antunes MJ. Non-cardioplegic coronary surgery in patients with severe left ventricular dysfunction. Eur J Cardiothorac Surg. 1999;16:331-6.
9. Underwood SR, Bax JJ, Vom Dahl J, et al. Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardology. Eur Heart J. 2004;25:815-36.
10. Mock MB, Ringqvist I, Fisher LD, et al. Survival of medically treated patients in the coronary artery surgery study (CASS) registry. Circulation. 1982;66(3):562-8.
11. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-42.
12. Cleland J, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet. 2003;362:14-21.
13. Knuesel PR, Nanz D, Wyss C, et al. Characterisation of dysfunctional myocardium by positron emission tomography and magnetic resonance: relation to functional outcome after revascularisation. Circulation. 2003; 108:1095-100.
14. Cwaig JM, Cwajg E, Nagueh SF, et al. End-diastolic wall thickness as a predictor of recovery of function in myocardial hibernation: relation to rest-redistribution T1-201 tomography and dobutamine stress echocardiography. J Am Coll Cardiol. 2000;35:1152-61.
15. Kolipaka A, Chatzimavroudis GP, White RD, Lieber ML, Setser RM. Relationship between the extent of non-viable myocardium and regional left ventricular function in chronic ischemic heart disease. J Cardiovasc Magn Reson. 2005;7(3):573-9.
16. Fleiss JL. Statistical methods for rates and proportions. 2nd Ed. New York; Wiley; 1981.
17. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39(7):1151-8.
18. Acampa W, Cuocolo A, Petretta M, et al. Tetrofosmin imaging in the detection of myocardial viability in patients with previous myocardial infarction: comparison with sestamibi and Tl-201 scintigraphy. J Nucl Cardiol. 2002;9:33-40.
19. Cuocolo A, Pace L, Ricciardelli B, et al. Identification of viable myocardium in patients with coronary artery disease: Comparison of thallium-201 scintigraphy with reinjection and technetium-99m methoxyisobutyl isonitrile. J Nucl Med. 1992;33:505-11.
20. Altehoefer C, Vom Dahl J, Biedermann M, et al. Significance of defect severity in technetium-99m-MIBI SPECT at rest to assess myocardial viability: comparison with fluorine-18-FDG PET. J Nucl Med. 1994;35:569-74.
21. 18F]fluorodeoxygluscose. Circulation. 1994;89: 578-87.
22. Burt RW, Perkins OW, Oppenheim BE, et al. Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium -201 SPECT for detection of myocardial viability. J Nucl Med. 1995;36:176-79.
23. 3/FDG PET. Scand Cardiovasc J. 2001;35:245-51.
24. Sawada SG, Allman KC, Muzik O, et al. Positron emission tomography detects evidence of viability in rest technetium-99m sestamibi defects. J Am Coll Cardiol. 1994;23:92-8.
25. Slart RH, Bax JJ, Sluiter WJ, et al. Added value of attenuation-corrected Tc-99m tetrofosmin SPECT for the detection of myocardial viability: comparison with FDG SPECT. J Nucl Cardiol. 2004;11:689-96.
26. Altehoefer C, Vom Dahl J, Messmer BJ, et al. Fate of the resting perfusion defect as assessed with technetium-99m methoxyisobutyl-isonitrile single-photon emission computed tomography after successful revascularisation in patients with healed myocardial infarction. Am J Cardiol. 1996;77:88-92.
27. Barnes E, Hall RJ, Dutka DP, Camici PG. Absolute blood flow and oxygen consumption in stunned myocardium in patients with coronary artery disease. J Am Coll Cardiol. 2002;39(3):420-7.
28. Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, et al. Uptake of the cation hexakis (2-methyoxyisobutylisonitrile) - technetium-99m by human carcinoma cell lines in vitro. Cancer Res. 1990;50:198-202.
29. Ono S, Takeishi Y, Yamaguchi H, et al. Enhanced regional washout of technetium-99m-sestamibi in patients with coronary spastic angina. Ann Nuc Med. 2003;17:393-8.
30. Camici PG, Dutka DP. Repetitive stunning, hibernation, and heart failure: contribution of PET to establishing a link. Am J Physiol Heart Circ Physiol. 2001;280(3):H929-36.
31. Klein C, Nekolla SG, Bengel FM, et al. Assessment of Myocardial Viability With Contrast - Enhanced Magnetic Resonance Imaging. Comparison with Positron Emission Tomography. Circulation. 2002;105:162-7.
32. Schuijf J, Kaandorp TA, Lamb HJ, et al. Quantification of myocardial infarct size and transmurality by contrast-enhanced magnetic resonance imaging in men. Am J Cardiol. 2004;94:284-28822.
33. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108(1):54-9.